ArticleNature2020
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1,554 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,554citing papers in PubMed, 2 pooled it
108.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,554 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,253 citations in OpenAlex.
- Pooled it
- Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort.Journal for immunotherapy of cancer · 2026Trial
- Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1.Cancer discovery · 2026Trial
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.International journal of radiation oncology, biology, physics · 2026Trial
- Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.Molecular cancer · 2026Trial
- Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.Frontiers in immunology · 2026Trial
- Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.Nature cancer · 2026Trial
- Efineptakin alfa (NT-I7) improves overall survival and induces immune niches in murine tumors.Genes & diseases · 2027Article
- Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.Oncoimmunology · 2026Article
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.Oncoimmunology · 2026Article
- Tertiary lymphoid structures in gastrointestinal cancer: orchestrating tumour microenvironmental immune subcycles to elegantly amplify the cancer immunity cycle.Annals of medicine · 2026Review
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.Experimental dermatology · 2026Review
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
1,494 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
25 authors at 9 institutions in 4 countries.
Rita Cabrita *Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Martin Lauss *Department of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Adriana SannaDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Marco DoniaNational Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Mathilde Skaarup LarsenDepartment of Clinical Pathology, Herlev University Hospital, Herlev, Denmark.
Shamik MitraDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Iva JohanssonDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Bengt PhungDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Katja HarbstDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Johan Vallon-ChristerssonDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Alison van SchoiackNanoString Technologies, Seattle, WA, USA.
Kristina LövgrenDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Sarah WarrenNanoString Technologies, Seattle, WA, USA.
Karin JirströmDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Håkan OlssonDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Kristian PietrasDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Center, Lund University, Lund, Sweden.
Christian IngvarDepartment of Surgery, Skåne University Hospital, Lund, Sweden.
Karolin IsakssonDepartment of Surgery, Skåne University Hospital, Lund, Sweden.
Dirk SchadendorfDepartment of Dermatology, University Hospital of Essen, Essen, Germany.
Henrik SchmidtDepartment of Oncology, Århus University Hospital, Aarhus, Denmark.
Lars BastholtDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Ana CarneiroDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden.
Jennifer A WargoDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Inge Marie SvaneNational Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Göran JönssonDepartment of Clinical Sciences, Division of Oncology and Pathology, Lund University Cancer Center, Lund University, Lund, Sweden. goran_b.jonsson@med.lu.se.
Lund University · SECopenhagen University Hospital · DKNanostring Technologies (United States) · USSkåne University Hospital · SEAarhus University Hospital · DKEssen University Hospital · DEHerlev Hospital · DKOdense University Hospital · DKThe University of Texas MD Anderson Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable tumour control and result in the long-term survival of patients with advanced cancers
Indexed as
Antigens, CD20B7-H1 AntigenB-LymphocytesCD8-Positive T-LymphocytesChemokine CXCL13HumansImmunologic MemoryMelanomaNeoplasm MetastasisPhenotypePrognosisProgrammed Cell Death 1 ReceptorProteomicsReceptors, CXCR5RNA-SeqSingle-Cell AnalysisAntigens, CD20B7-H1 AntigenChemokine CXCL13CXCL13 protein, humanCXCR5 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CXCR5T Cell Transcription Factor 1TCF7 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.